|  |  | 

India Top Headlines

Government Says Measure to Use Covaxin Now Justified | India News


NEW DELHI: The government said that the regular emergency use authorization for Covaxin from Bharat Biotech outside of ‘clinical trial mode’ was validation of India’s timely decision-making based on scientific evidence and that the production of Covaxin will increase with your use.
Dr VK Paul, a member of Niti Aayog (health), said that Covaxin was granted permission for regular emergency use authorization and that both Covid-19 vaccines, Covaxin from Bharat Biotech and Covishield from the Serum Institute, now had the same license status. “The vaccine has stood the test of time in terms of great safety. It is a triumph for the Indian science and technology company and R&D company as well as our industry, and I congratulate the ICMR and Bharat Biotech teams, ”said Paul.
Both Covishield and Covaxin received USA on January 3. However, in the absence of efficacy data from phase 3 trials, Covaxin received EUA under the “clinical trial mode” which required vaccinators to obtain informed consent from recipients prior to inoculation. It also meant that Bharat Biotech was responsible for compensation in case of adverse events according to the rules of clinical trials.

Reference page